WT staining in these cases effectively excludes the possibility of homozygous deletion of TP53. The prevalence of TP53 mutations in EC was 8.8% in our series, which is similar to reports for endometrioid carcinomas of the ovary (7%) 54 and endometrium (9%) 55 but remarkably lower compared to 51% (N = 37/72) from previous reports that included high‐grade carcinomas, which are now classified as HGSOC 56. This evidence concerns the gene TP53 and ovarian endometrioid adenocarcinoma.